

## Panos Macheras PUBLICATIONS 2013-2023

1. M. SYMILLIDES, V. KARALIS, P. MACHERAS. Exploring the relationships between scaled bioequivalence limits and within-subject variability. *Journal of Pharmaceutical Sciences* 102, 296-301 (2013).
2. J. KYTARIOLOS, G. CHARKOFTAKI, J.R. SMITH, G. VOYIATZIS, A. CHRISANTHOPOULOS, S.N. YANNOPOULOS, D.G. FATOUROS, P. MACHERAS. Stability and physicochemical characterization of novel milk-based oral formulations. *International Journal of Pharmaceutics*. 444, 128-138 (2013).
3. V. KARALIS, P. MACHERAS. An insight into the properties of a two-stage design in bioequivalence studies. *Pharmaceutical Research*. 30, 1824-1835 (2013).
4. P. MACHERAS, V. KARALIS, G. VALSAMI. Keeping a critical eye on the science and the regulation of oral drug absorption: a review. *Journal of Pharmaceutical Sciences* 102, 3018-3036 (2013).
5. A. ZAJICEK, M.J. FOSSLER, J.S. BARRETT, J.H. WORTHINGTON, R. TERNIK, D. MCLAREN, G. CHARKOFTAKI, S. LUM, J. BREITKREUTZ, M. BALTHAZAR, P. MACHERAS, M. KHAN, S. AGHARKAR. A report from the AAPS pediatric formulations task force: perspectives on the state of child-friendly dosage forms (AAPS Paediatric Task Force Group), *AAPS Journal* 15:1072-1081 (2013).
6. N. PISPA, A. DOKOUMETZIDIS, C. DEMETZOS, P. MACHERAS. On the ubiquitous presence of fractals and fractal concepts in pharmaceutical sciences: A review. *International Journal of Pharmaceutics*. 456, 340-352 (2013).
7. V. KARALIS, M. BIALER, P. MACHERAS. Quantitative assessment of the switchability of generic products. *European Journal of Pharmaceutical Sciences* 50, 476-483 (2013).
8. V. KARALIS, P. MACHERAS, M. BIALER. Generic products of antiepileptic drugs: A perspective on bioequivalence, bioavailability and galenic versus generic formulation switches using Monte Carlo simulations. *CNS Drugs*. 28, 69-77 (2014).
9. V. KARALIS, P. MACHERAS. On the statistical model of the two-stage designs in bioequivalence assessment. *J. Pharm Pharmacol* 66, 48-52 (2014).
10. P. MACHERAS, V. KARALIS. A non-binary biopharmaceutical classification of drugs: the ABΓ system. *International Journal of Pharmaceutics*. 464, 85-90 (2014).
11. P. MACHERAS. Comment and reply on: A randomized crossover trial investigating the ease of use and preference of two dry powder inhalers in patients with asthma of chronic obstructive pulmonary disease. *Expert. Opin. Drug. Deliv.* 11, 1-3 (2014).
12. C. DAOUSANI, P. MACHERAS. Scientific considerations concerning the EMA change in the definition of "Dose" of the BCS-based biowaiver guideline. *International Journal of Pharmaceutics* 478, 606-609 (2015).
13. P. MACHERAS, K. SOULELE. Milk as a medium for paediatric formulations: experimental findings and regulatory aspects. *International Journal of Pharmaceutics*. 492, 344-345 (2015).
14. K. SOULELE, L. SILVESTRO, S. SAVU RIZEA, P. MACHERAS, V. KARALIS. A population pharmacokinetic study of fluticasone propionate/salmeterol in healthy

- subjects using two different dry powder inhalers. *European Journal of Pharmaceutical Sciences*. 80, 33-42 (2015).
15. C. DAOUSANI, P. MACHERAS. Biopharmaceutic classification of drugs revisited. *European Journal of Pharmaceutical Sciences*. 95, 82-87 (2016).
  16. K. SOULELE, P. MACHERAS, V. KARALIS. Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers. *Biopharmaceutics & Drug Disposition*. 2017, 1-13, <https://doi.org/10.1002/bdd2077>.
  17. P. SOPASAKIS, C. SARIMVEIS, P. MACHERAS, A. DOKOUMETZIDIS. Fractional calculus in Pharmacokinetics. *Journal of Pharmacokinetics and Pharmacodynamics*. 2017, doi: 10.1007/s10928-017-9547-8.
  18. K. SOULELE, P. MACHERAS, V. KARALIS. On the pharmacokinetics of inhaled budesonide/formoterol combination in asthma patients using modeling approaches. *Pulmonary Pharmacology & Therapeutics* 48, 168-178 (2018).
  19. K. KOSMIDIS, P. MACHERAS. On the dilemma of fractal or fractional kinetics in drug release studies: A comparison between Weibull and Mittag-Leffler functions. *International Journal of Pharmaceutics* 543, 269-273 (2018).
  20. P. MACHERAS, A. ILIADIS, G. MELAGRAKI. A reaction-limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs. *European Journal of Pharmaceutical Sciences*. 117, 98-106 (2018).
  21. P. MAVROUDIS, K. KOSMIDIS, P. MACHERAS. On the unphysical hypotheses in pharmacokinetics and oral drug absorption: Time to utilize instantaneous rate coefficients instead of rate constants. *European Journal of Pharmaceutical Sciences*. 130, 137-146 (2019).
  22. A. CHARALABIDIS, M. SFOUNI, C. BERGSTROM, P. MACHERAS. BCS and BDDCS: Beyond guidelines (Invited review). *International Journal of Pharmaceutics*. 566, 264-281 (2019)
  23. P. MACHERAS. On an unphysical hypothesis of Bateman equation and its implications for pharmacokinetics. *Pharmaceutical Research*. (2019) 36:94 <https://doi.org/10.1007/s11095-019-2633-4>
  24. K. KOSMIDIS, P. MACHERAS. A fractal kinetics SI model can explain the dynamics of COVID-19 epidemics. (2020). PLoS ONE 15(8): e0237304. <https://doi.org/10.1371/journal.pone.0237304>
  25. P. MACHERAS, P. CHRYSSAFIDIS. Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts. *Pharm Res* 37, 187 (2020). <https://doi.org/10.1007/s11095-020-02894-w> (cover page of the issue). Erratum/ *Pharm Res* 37, 206 (2020). <https://doi.org/10.1007/s11095-020-02935-4>
  26. P. MACHERAS, K. KOSMIDIS, P. CHRYSSAFIDIS. Demystifying the spreading of pandemics I: The fractal kinetics SI model quantifies the dynamics of COVID-19, medRxiv 2020.11.15.20232132; doi: <https://doi.org/10.1101/2020.11.15.20232132>
  27. P. MACHERAS, C. DI PAOLO, Y. PUSICA, E. P. DIAMANDIS. From Camille Noúç to Apollonian and the Dionysian scientists. Diagnosis. 2021/6/23.

28. P. MACHERAS, A. TSEKOURAS, P. CHRYSSAFIDIS. "Interpreting airborne pandemics spreading using fractal kinetics' principles" *F1000Research* **10**, 609 (2021) [DOI: [10.12688/f1000research.53196.1](https://doi.org/10.12688/f1000research.53196.1)]
29. P. CHRYSSAFIDIS, A. A. TSEKOURAS, P. MACHERAS. Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations, *Pharmaceutical Research* **38**, 1345–1356 (2021) [DOI: [10.1007/s11095-021-03078-w](https://doi.org/10.1007/s11095-021-03078-w)]
30. K. SOULELE, T. KARAMBELAS, C. TAMVAKOPOYLOS, P. MACHERAS. Enhancement of Docetaxel Absorption Using Ritonavir in an Oral Milk-based Formulation *Pharmaceutical Research* **38**, 1419–1428 (2021)
31. A. A. TSEKOURAS, P. MACHERAS. Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts. *Pharmaceutical Research* (2021) [DOI: [10.1007/s11095-021-03121-w](https://doi.org/10.1007/s11095-021-03121-w)]
32. P. MACHERAS. Drugs are Absorbed in Finite Time: A New Era in Biopharmaceutics and Pharmacokinetics. *Acta Pharmaceutica Hungarica*. **85**, 148-149 (2021) DOI:10.33892/aph.2021.91.148-149
33. P. CHRYSSAFIDIS, A. A. TSEKOURAS, P. MACHERAS. Re-writing oral pharmacokinetics using physiologically based finite time pharmacokinetic (PBFTPk) models. *Pharm. Res.* 2022;39:.. <https://doi.org/10.1007/s11095-022-03230-0>.
34. D. WU, A.A. TSEKOURAS, P. MACHERAS, F. KESISOGLU. Physiologically based pharmacokinetic models under the prism of the finite absorption time concept. *Pharm. Res.* **39**,(2022) [DOI: [10.1007/s11095-022-03357-0](https://doi.org/10.1007/s11095-022-03357-0)]
35. P. MACHERAS, A. A. TSEKOURAS. Columbus' egg: Oral drugs are absorbed in finite time *Eur. J. Pharm. Sci.* **176**, 106265 (2022) [DOI: [10.1016/j.ejps.2022.106265](https://doi.org/10.1016/j.ejps.2022.106265)]
36. A. A. TSEKOURAS, P. MACHERAS. The Finite Absorption Time (FAT) Concept en route to PBPK modeling and pharmacometrics. *J. Pharmacokin. Pharmacodyn.* **62**, (2022) [DOI: [10.1007/s10928-022-09832-w](https://doi.org/10.1007/s10928-022-09832-w)]
37. N. ALIMPERTIS, A. A. TSEKOURAS, P. MACHERAS Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption. *The journal of controlled release*. Submitted (April 30, 2023)